Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643745 | 0.84 | NPC1 (0.66) | HDAC6HDAC1DRD2TBXA2RNPC1 | |
| SCHEMBL28806937 | 0.80 | TP53 (0.57) | DRD2TBXA2RNPC1RAB9A | |
| SCHEMBL21660693 | 0.79 | TSHR (0.55) | TSHRDRD2TBXA2RNPC1RAB9A | |
| SCHEMBL2119872 | 0.76 | HDAC8 (0.46) | HDAC6HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL11707540 | 0.76 | RAB9A (0.69) | TSHRNPC1RAB9A | |
| SCHEMBL28809095 | 0.74 | TP53 (0.55) | DRD2TBXA2RNPC1RAB9A | |
| SCHEMBL5089620 | 0.73 | RAB9A (0.70) | TSHRNPC1RAB9A | |
| SCHEMBL20595491 | 0.73 | HDAC6 (0.63) | HDAC6HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL21660948 | 0.71 | NPC1 (0.56) | HDAC6HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL2302453 | 0.71 | HDAC1 (0.71) | HDAC6HDAC1HDAC8HDAC3HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-02-06 | — | — | US | disclosed |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-02-06 | — | — | US | disclosed |
| CN-110730660-A | Nrf and HIF activators/HDAC inhibitors and methods of treatment using the same | 伊利诺伊大学评议会 | 2020-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | HIF1AN, KEAP1, NFE2L2 | TSHR 3525/4885HDAC6 35/4885HDAC1 11/4885 |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HIF1AN, KEAP1, NFE2L2 | TSHR 3525/4885HDAC6 35/4885HDAC1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.